PBH
AI MemoPrestige Consumer Healthcare
As of 2026-10-30/Confidence medium
Data freshness
AI Memo
As of 2026-10-30 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Action
—
Confidence
medium
Horizon
—
Key catalyst
Fiscal 2027 second-quarter results on November 5 • 2026-11-05
Base target: $52 / p=50% prob
Biggest risk
Reported diluted EPS fell to $0.61 from $0.95, acquisition adjustments widened the gap to adjusted EPS, and approximately $2 billion of net debt raises execution sensitivity. Management also cited a challenging consumer backdrop and Clear Eyes variability. [#SEC-8K-2026-08-06]
Invalidation
Break below $39 or thesis failure.
What would change my mind?
Fiscal first-quarter revenue rose 6.5%, including 3.2% organic growth, and adjusted diluted EPS rose to $0.98 from $0.95. Durable brand growth, acquisition integration and deleveraging could support a rerating. [#SEC-8K-2026-08-06]
Research note
Recommendation
—
Confidence
medium
As of
2026-10-30
Base target
$52
p=50%
Bull target
$62
p=25%
Bear target
$39
p=25%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- Breathe Right and LaCorium integration
- Cash conversion and deleveraging
- Fiscal first-quarter revenue rose 6.5%, including 3.2% organic growth, and adjusted diluted EPS rose to $0.98 from $0.95.
BearKey bullets
- Acquisition and facility-optimization costs complicate comparisons between reported and adjusted earnings.
- [#SEC-8K-2026-08-06]
- Approximately $2 billion of net debt makes sustained cash generation and integration important.
WatchKey bullets
- Fiscal 2027 second-quarter results on November 5
Summary
High-level snapshot
Recommendation
-
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
-
Base case: $52 (p=50%)
Target spread vs base: +19% / -25%
Scenario probabilities
Bull Target: $62 (p=25%)Base Target: $52 (p=50%)Bear Target: $39 (p=25%)
Commentary
The supplied recent-news item is unrelated to PBH. No verified post-result price reaction, analyst revisions, options, short-interest, employee or social measures are available; zero-valued sentiment fields mean unavailable data, not measured neutrality. The deterministic prior is modestly positive, but November 5 results remain the principal test.
As of 2026-10-30 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
Fiscal first-quarter revenue rose 6.5%, including 3.2% organic growth, and adjusted diluted EPS rose to $0.98 from $0.95. Durable brand growth, acquisition integration and deleveraging could support a rerating. [#SEC-8K-2026-08-06]
Bear Case
Reported diluted EPS fell to $0.61 from $0.95, acquisition adjustments widened the gap to adjusted EPS, and approximately $2 billion of net debt raises execution sensitivity. Management also cited a challenging consumer backdrop and Clear Eyes variability. [#SEC-8K-2026-08-06]
Drivers
Scannable catalysts and supporting factors
- Breathe Right and LaCorium integration
- Cash conversion and deleveraging
Scenarios
Bull Target (Scenario probability)
$62 / p=25% prob
Base Target (Scenario probability)
$52 / p=50% prob
Bear Target (Scenario probability)
$39 / p=25% prob
Analysis 2026-10-30 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
News Sentiment (30d)
0.00
Social Sentiment (7d)
0.00
Events
Other notable items detected
- EVENT2026-11-05Fiscal 2027 second-quarter results on November 5The company scheduled its earnings release and call for November 5. The decision point is whether organic sales, adjusted earnings and cash generation support the fiscal 2027 outlook of $1.290–$1.315 billion in revenue and $4.55–$4.65 in adjusted diluted EPS, which was raised to include acquisitions. [#PR-EARNINGS-2026-10-14] [#SEC-8K-2026-08-06]Prob 60.00% • Move 7.00% • Priced-in 50.00%
Short-term Catalysts
Next few weeks
No short-term catalysts
Long-term Catalysts
Months to a year
- Breathe Right and LaCorium integration2027-03-31Breathe Right contributed approximately $5.9 million in the fiscal first quarter after its June acquisition; LaCorium closed in July. Subsequent results can test sustained brand contribution and integration costs, but gains beyond the reported quarter are not yet established. [#SEC-8K-2026-08-06]Prob 60% • Move 10% • Priced-in 45%
- Cash conversion and deleveraging2027-03-31Net debt was approximately $2 billion at June 30. Management expects to deleverage, but first-quarter adjusted free cash flow benefited from working-capital timing; sustained cash conversion after acquisition costs remains to be demonstrated. [#SEC-8K-2026-08-06]Prob 55% • Move 6% • Priced-in 40%
Risks
- Acquisition and facility-optimization costs complicate comparisons between reported and adjusted earnings. [#SEC-8K-2026-08-06]
- Approximately $2 billion of net debt makes sustained cash generation and integration important. [#SEC-8K-2026-08-06]
- Consumer softness and Clear Eyes variability could offset growth in other categories. [#SEC-8K-2026-08-06]
- The senior vice president of operations retired effective August 14; the filing does not establish an operating impact. [#8-K-2026-08-14]
Peers
| Symbol | Summary |
|---|---|
| PRGO | Perrigo is an OTC and consumer self-care operating comparator, though its portfolio and financial profile differ from PBH's. Perrigo investor relations |
| HLN | Haleon overlaps in consumer-health products, but its much larger global scale limits direct valuation comparison. Haleon investor relations |
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-10-30